Lesson plan

VCU-1012

VCU-1012, also known as 1-quinazolin-2-ylpiperazine or as 3-azaquipazine, is a psychedelic drug of the arylpiperazine family related to quipazine (1-(2-quinolinyl)piperazine). It is a serotonin 5-HT 2A receptor agonist and produces psychedelic-like effects in rodents similarly to quipazine, but lacks quipazine's serotonin 5-HT 3 receptor agonism and associated gastrointestinal adverse effects like nausea and vomiting. The drug represents a novel structural class of psychedelics distinct from existing scaffolds.

Back to article

Article summary

VCU-1012, also known as 1-quinazolin-2-ylpiperazine or as 3-azaquipazine, is a psychedelic drug of the arylpiperazine family related to quipazine (1-(2-quinolinyl)piperazine). It is a serotonin 5-HT 2A receptor agonist and produces psychedelic-like effects in rodents similarly to quipazine, but lacks quipazine's serotonin 5-HT 3 receptor agonism and associated gastrointestinal adverse effects like nausea and vomiting. The drug represents a novel structural class of psychedelics distinct from existing scaffolds.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.